Hoffman Robert E. 4

What Happened

• Robert E. Hoffman, Chief Financial Officer of CytoDyn Inc. (CYDY), was granted an award of 4,874,691 shares on March 20, 2026. The grant is reported as a derivative acquisition at $0.00 per share (transaction code A — Award/Grant) and therefore shows no immediate cash value on grant. The award was made under the Company’s 2012 Equity Incentive Plan.

Key Details

• Transaction date: 2026-03-20; filing date: 2026-03-24 (appears to be 4 days after the transaction; potentially late under the Form 4 two-business-day rule).
• Shares granted: 4,874,691; reported acquisition price: $0.00 (award).
• Vesting: 1,218,672 shares vest on March 20, 2027; the remaining 3,656,019 shares vest in approximately equal monthly installments beginning April 2027 through March 2030 (~101,556 shares/month).
• Source/authority: Approved by the Compensation Committee and issued from shares reserved under the 2012 Equity Incentive Plan (per filing footnotes).
• Shares owned after the transaction: not disclosed in the provided filing details.

Context

• This is a compensation award (not an open-market purchase or sale). Such grants are routine for executive pay and indicate future potential ownership only as shares vest. Because the award vests over several years, it does not represent immediate liquidity or a sale.